GlassScriptPhysician profile
Stella Wong
NPI 1861265688
$1,993.91
in general payments reported to CMS, 2019-2025
32 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $984 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $259.99 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $226.39 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Sobi, INC | $217.15 | 2024-2025 | |
| Abbvie INC. | $118.40 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.00 | 2024 | Ninlaro, Alunbrig, Fruzaqla |
| Celltrion USA INC. | $83.54 | 2024-2025 | Vegzelma |
| Bayer Healthcare Pharmaceuticals INC. | $83.52 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $80.82 | 2024-2025 | Alymsys, Avastin |
| Genzyme Corporation | $62.56 | 2025 | |
| Pfizer INC. | $60.92 | 2024-2025 | |
| Incyte Corporation | $55.93 | 2024-2025 | Jakafi |
| Daiichi Sankyo INC. | $49.52 | 2024-2025 | Injectafer, Enhertu |
| Pharmacosmos Therapeutics INC. | $46.66 | 2024 | Monoferric |
| Beigene USA, INC. | $44.32 | 2024-2025 | Tevimbra |
| Lilly USA, LLC | $42.03 | 2024-2025 | Jaypirca, Retevmo, Verzenio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $41.78 | 2024 | Vyloy, Padcev |
| Deciphera Pharmaceuticals INC. | $40.76 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Almirall LLC | $39.80 | 2025 | Klisyri |
| Stemline Therapeutics INC. | $32.19 | 2024 | Orserdu |
| Janssen Biotech, INC. | $32.16 | 2025 | Rybrevant |
| Emd Serono, INC. | $31.05 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $31.01 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $30.20 | 2025 | |
| Beone Medicines USA, INC. | $25.84 | 2025 | Tevimbra |
| Exelixis INC. | $25.08 | 2024 | Cabometyx |
| Arcutis Biotherapeutics, INC. | $23.54 | 2025 | Zoryve |
| Array Biopharma INC | $21.32 | 2024 | Lorbrena, Braftovi |
| Myriad Genetic Laboratories, INC. | $19.71 | 2025 | Myrisk |
| Alnylam Pharmaceuticals INC. | $18.46 | 2025 | Givlaari |
| Kite Pharma, INC. | $18.30 | 2025 | Yescarta |
| Tolmar, INC. | $15.96 | 2024 | |
| Biowound Solutions, INC. | $10.00 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.